Perspective Therapeutics to Provide Several Upcoming Corporate Updates
Rhea-AI Summary
Perspective Therapeutics (NYSE AMERICAN: CATX) will deliver multiple corporate updates and investor events in May 2026, including an analyst event, a press-release-only first quarter 2026 financial results posting, and two conference fireside chats.
Key dates: May 4 analyst event at 8:30 a.m. ET; May 11 Q1 2026 press release after market close; May 13 BofA fireside chat at 2:20 p.m. PT; May 19 RBC fireside chat at 2:05 p.m. ET. Webcasts will be posted on the company website unless noted.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CATX
On the day this news was published, CATX declined NaN%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.2% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows 2 peers (e.g., QSI, BWAY) moving up with median gains around 4.1%, indicating broader sector strength alongside CATX.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | Clinical data update | Positive | +8.3% | Updated interim Phase 1/2a [212Pb]VMT-α-NET data at AACR 2026. |
| Apr 02 | Investor conferences | Neutral | -0.2% | Participation in April investor events and availability for 1x1 meetings. |
| Mar 17 | Conference acceptance | Positive | -1.8% | AACR acceptance of updated [212Pb]VMT-α-NET data for poster presentation. |
| Mar 16 | Earnings and update | Negative | -5.2% | Full year 2025 results with larger net loss and higher R&D spend. |
| Feb 17 | Earnings scheduling | Neutral | +3.2% | Announcement of timing for full year 2025 results and business update. |
News has produced mixed reactions: strong gains on positive clinical data, sell‑offs around earnings, and occasional divergence on conference or announcement headlines.
Over the last few months, CATX has highlighted Phase 1/2a data for [212Pb]VMT-α-NET, presented at AACR with a favorable initial market reaction of +8.33%. Earlier AACR acceptance news in mid‑March saw a modest decline, while full‑year 2025 results and business updates on March 16, 2026 coincided with a -5.17% move. Conference participation and scheduling announcements have generally produced muted or mixed price responses, framing today’s corporate‑update scheduling as part of an ongoing investor‑relations cadence.
Market Pulse Summary
This announcement outlines a series of May 2026 touchpoints, including an analyst event on May 4, first‑quarter 2026 results on May 11, and healthcare conference appearances on May 13 and May 19. These follow recent AACR data and 2025 results, where market responses have varied between gains and sell‑offs. Investors watching this cadence often focus on the substance of clinical updates, financial trends, and messaging consistency across these scheduled events.
Key Terms
radiopharmaceutical medical
AI-generated analysis. Not financial advice.
SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will provide several corporate updates in May 2026. Webcasts of these events, unless noted as press release only, will be posted on the Company's website at www.perspectivetherapeutics.com.
Analyst Event on Perspective’s Strategy, Enabling Technology, and Pipeline
Additional details are available here.
Date: May 4, 2026
Time: 8:30 a.m. ET
First Quarter 2026 Financial Results – Press Release Only
The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.
Date: May 11, 2026
Time: After the market closes
BofA Securities Health Care Conference – Fireside Chat
Date: May 13, 2026
Time: 2:20 p.m. PT / 5:20 p.m. ET
2026 RBC Capital Markets Global Healthcare Conference – Fireside Chat
Date: May 19, 2026
Time: 2:05 p.m. ET
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s expectations regarding its interactions with regulatory agencies and the expected timing thereof; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contact:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
